Literature DB >> 22505840

Cysteine Protease Cathepsins in Atherosclerosis and Abdominal Aortic Aneurysm.

Sara Sjöberg1, Guo-Ping Shi.   

Abstract

Extracellular matrix remodeling is an important mechanism in the initiation and progression of cardiovascular diseases. Cysteine protease cathepsins are among the important proteases that affect major events in the pathogenesis of atherosclerosis and abdominal aortic aneurysm, including smooth muscle cell transmigration through elastic lamina, macrophage foam cell formation, vascular cell and macrophage apoptosis, and plaque rupture. These events have been studied in cathepsin deficiencies and cathepsin inhibitor deficiencies in mice and have provided invaluable insights regarding the roles of cathepsins in cardiovascular diseases. Pharmacological inhibitions for cathepsins are under evaluation for other human diseases and may be used as clinical treatments for cardiovascular diseases in the near future. This article reviews different mechanisms for cathepsins in atherosclerosis and abdominal aortic aneurysm that could be targeted by selective cathepsin inhibitors.

Entities:  

Year:  2011        PMID: 22505840      PMCID: PMC3324310          DOI: 10.1007/s12018-011-9098-2

Source DB:  PubMed          Journal:  Clin Rev Bone Miner Metab        ISSN: 1534-8644


  82 in total

Review 1.  Recent developments in cathepsin K inhibitor design.

Authors:  Urszula Grabowskal; Timothy J Chambers; Masahiro Shiroo
Journal:  Curr Opin Drug Discov Devel       Date:  2005-09

2.  Destabilizing role of cathepsin S in murine atherosclerotic plaques.

Authors:  Kenneth J Rodgers; Deborah J Watkins; Alastair L Miller; Peter Y Chan; Sharada Karanam; William H Brissette; Clive J Long; Christopher L Jackson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-01-12       Impact factor: 8.311

Review 3.  The immune response in atherosclerosis: a double-edged sword.

Authors:  Göran K Hansson; Peter Libby
Journal:  Nat Rev Immunol       Date:  2006-06-16       Impact factor: 53.106

Review 4.  Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency.

Authors:  Ira Tabas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-09-01       Impact factor: 8.311

5.  Apoptotic death of inflammatory cells in human atheroma.

Authors:  W Li; H Dalen; J W Eaton; X M Yuan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-07       Impact factor: 8.311

Review 6.  Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.

Authors:  Zorina S Galis; Jaikirshan J Khatri
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

Review 7.  Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis.

Authors:  S-O Olofsson; J Borèn
Journal:  J Intern Med       Date:  2005-11       Impact factor: 8.989

8.  Cathepsin K gene disruption does not affect murine aneurysm formation.

Authors:  Lili Bai; Linda Beckers; Erwin Wijnands; Suzanne P M Lutgens; M Verónica Herías; Paul Saftig; Mat J A P Daemen; Kitty Cleutjens; Esther Lutgens; Erik A L Biessen; Sylvia Heeneman
Journal:  Atherosclerosis       Date:  2009-09-06       Impact factor: 5.162

9.  Role of cathepsin K in structural changes in brachiocephalic artery during progression of atherosclerosis in apoE-deficient mice.

Authors:  Andriy O Samokhin; Andre Wong; Paul Saftig; Dieter Brömme
Journal:  Atherosclerosis       Date:  2008-03-04       Impact factor: 5.162

10.  Differential expression of cysteine and aspartic proteases during progression of atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Sofia Jormsjö; Dirk M Wuttge; Allan Sirsjö; Carl Whatling; Anders Hamsten; Sten Stemme; Per Eriksson
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

View more
  7 in total

1.  Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects.

Authors:  Christopher D Payne; Mark A Deeg; Melanie Chan; Lai Hock Tan; Elizabeth Smith LaBell; Tong Shen; David J DeBrota
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

2.  Pharmaceutical stabilization of mast cells attenuates experimental atherogenesis in low-density lipoprotein receptor-deficient mice.

Authors:  Jing Wang; Sara Sjöberg; Viviane Tia; Blandine Secco; Han Chen; Min Yang; Galina K Sukhova; Guo-Ping Shi
Journal:  Atherosclerosis       Date:  2013-06-07       Impact factor: 5.162

3.  The HIV Protease Inhibitor Saquinavir Inhibits HMGB1-Driven Inflammation by Targeting the Interaction of Cathepsin V with TLR4/MyD88.

Authors:  John P Pribis; Yousef Al-Abed; Huan Yang; Domokos Gero; Hongbo Xu; Marcelo F Montenegro; Eileen M Bauer; Sodam Kim; Sangeeta S Chavan; Changchun Cai; Tunliang Li; Petra Szoleczky; Csaba Szabo; Kevin J Tracey; Timothy R Billiar
Journal:  Mol Med       Date:  2015-09-02       Impact factor: 6.354

Review 4.  Cathepsins: a new culprit behind abdominal aortic aneurysm.

Authors:  Yi Wang; Chaoshu Tang; Yanwen Qin
Journal:  Regen Med Res       Date:  2013-11-01

5.  Effect of poloxamer 407 administration on the serum lipids profile, anxiety level and protease activity in the heart and liver of mice.

Authors:  Tatyana A Korolenko; Thomas P Johnston; Nina I Dubrovina; Yana A Kisarova; Svetlana Ya Zhanaeva; Marina S Cherkanova; Elena E Filjushina; Tatyana V Alexeenko; Eva Machova; Natalya A Zhukova
Journal:  Interdiscip Toxicol       Date:  2013-03

6.  Proteolytic characteristics of cathepsin D related to the recognition and cleavage of its target proteins.

Authors:  Huiying Sun; Xiaomin Lou; Qiang Shan; Ju Zhang; Xu Zhu; Jia Zhang; Yang Wang; Yingying Xie; Ningzhi Xu; Siqi Liu
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

Review 7.  Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases.

Authors:  Hongxian Wu; Qiuna Du; Qiuyan Dai; Junbo Ge; Xianwu Cheng
Journal:  J Atheroscler Thromb       Date:  2017-10-05       Impact factor: 4.928

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.